Advertisement


Thierry André, MD, and Michael J. Overman, MD, on Colorectal Cancer: Results From Two CheckMate-142 Trials

2018 Gastrointestinal Cancers Symposium

Advertisement

Thierry André, MD, of Hôpital Saint-Antoine, and Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from their respective CheckMate-142 studies on nivolumab and ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer (Abstracts 553, 554).



Related Videos

Gastroesophageal Cancer
Gastrointestinal Cancer

Manish A. Shah, MD, on Gastric Cancer: Results From the RAINFALL Trial

Manish A. Shah, MD, of Weill Cornell Medicine, discusses phase III study findings on cisplatin plus capecitabine or fluorouracil with or without ramucirumab as first-line therapy i...

Gastroesophageal Cancer

Basem Azab, MD, on Esophageal Cancer: Study Survival Results

Basem Azab, MD, of the Sylvester Comprehensive Cancer Center, University of Miami, discusses the impact on overall survival when more than 2 months elapse between finishing neoadju...

Gastroesophageal Cancer

David H. Ilson, MD, PhD, on Improving Esophageal Cancer Outcomes: Future Directions

David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent resu...

Gastrointestinal Cancer
Immunotherapy

Florian Lordick, MD, on Gastric Cancer: Final Results From the AIO Trial

Florian Lordick, MD, of the University Medicine Leipzig, discusses study findings on intraperitoneal immunotherapy with the antibody catumaxomab for patients with peritoneal carcin...

Gastroesophageal Cancer

Abraham J. Wu, MD, on Esophageal Cancer: Impact of Lung and Heart Dose on Survival After Radiotherapy

Abraham J. Wu, MD, of Memorial Sloan Kettering Cancer Center, discusses his findings that suggest efforts to reduce lung dose, such as shrinking the treatment volumes or usin...

Advertisement

Advertisement



Advertisement